leisure time -WSS

leisure time

author：knowledge 2025-10-09 00:44:37 - browse：1

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Future doctors should be trained to promote social change

hotspot

WSS

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Stop the failed accountable care organization experiment

Male and female sex labels in research insufficient, scientists say

HHS secretary Becerra pressed on Change HealthCare cyberattack

How many hemophilia patients actually want gene therapy?

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Anesthesiologist group: stop taking Ozempic before surgery

CVS Caremark has created a new ploy: the drug ‘rebate credit’

FDA approval of Sarepta Duchenne genetic therapy gives me hope

UCLA team creates talking throat patch for voice disorders

How one medical school became remarkably diverse

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Novavax promises a turnaround & Lilly roils the obesity market

Stop the failed accountable care organization experiment

The cancer drug shortage isn’t new — and neither are the solutions

U.K. researchers warn about biases in medical devices, algorithms

explore

UCLA team creates talking throat patch for voice disorders

CVS Caremark has created a new ploy: the drug ‘rebate credit’

RaDonda Vaught links Vanderbilt hospital issues to patient death

AstraZeneca to buy developer of next

How many hemophilia patients actually want gene therapy?

Pushing for an NIH office for post

hotspot

entertainment

hotspot

explore